Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

Scriptaid

HY-15489

(GCK 1026; Scriptide; GCK1026; GCK-1026)

Scriptaid

Scriptaid Chemical Structure

Scriptaid(Scriptide; GCK-1026) is an inhibitor of HDAC; shows a greater effect on acetylated H4 than H3.

Size Price Stock Quantity
10 mM * 1 mL in DMSO $121 In-stock
10 mg $110 In-stock
50 mg $440 In-stock
100 mg Get quote
200 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €119 In-stock
10 mg €108 In-stock
50 mg €431 In-stock
100 mg Get quote
200 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: Scriptaid
Cat. No.: HY-15489

Scriptaid Data Sheet

  • View current batch:

    Purity: 99.25%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

Related Compound Libraries

Biological Activity of Scriptaid

Scriptaid(Scriptide; GCK-1026) is an inhibitor of HDAC; shows a greater effect on acetylated H4 than H3.
IC50 Value:
Target: HDAC
in vitro:  Scriptaid induces high rates of somatic cell nuclear transfer (SCNT) oocytes development to the blastocyst stage and allowed full-term development (3.4, 4.2, 7.6, 6.8, and 4.1%) with all concentrations (50, 100, 250, 500, and 2000 nM respectively). Scriptaid improves the full-term development of cloned B6D2F1embryos in a dose-dependent manner with the maximum effect at 250 nM. Scriptaid enables the clone of all the important inbred mouse strains, such as C57BL/6, C3H/He, DBA/2, and 129/Sv. Scriptaid treatment enhances newly synthesized mRNA levels in cloned embryos. 250 nM Scriptaid treated for up to 48 h, does not inhibit the development of ICSI-fertilized embryos. Scriptaid inhibits T. gondii tachyzoite proliferation with IC50 of 39 nM. Scriptaid (0.225 μM) completely protects the HS68 monolayers from T. gondii tachyzoite.
in vivo: Scriptaid elicits a dose-dependent decrease in lesion size (a maximal decrease of 45%) at 1.5 to 5.5 mg/kg and a concomitant attenuation in motor and cognitive deficits when delivered 30 minutes postinjury in a model of mode rate TBI. Comparable protection is achieved even when treatment is delayed to 12 h postinjury. The protection of motor and cognitive functions is long lasting, as similar improvements are detected 35 days postinjury. Scriptaid induces an increase in surviving neurons (42%), as well as the number/length of their processes within the CA3 region of the hippocampus and the pericontusional cortex. Scriptaid treatment prevents the decrease in phospho-AKT (p-AKT) and phosphorylated phosphatase and tensin homolog deleted on chromosome 10 ( p-PTEN) induced by TBI in cortical and CA3 hippocampal neurons. Scriptaid treatment (3.5 mg/kg) clearly inhibits tumor growth in a human breast cancer xenograft MDA-MB-231 model, reducing tumor volume by 75%.

Chemical Information

M.Wt 326.35 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C18H18N2O4
CAS No 287383-59-9
Solvent & Solubility

100 mM in DMSO;

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 3.0642 mL 15.3210 mL 30.6419 mL
5 mM 0.6128 mL 3.0642 mL 6.1284 mL
10 mM 0.3064 mL 1.5321 mL 3.0642 mL

References on Scriptaid

Inhibitor Kit

Related HDAC Products

  • ACY-1215

    Rocilinostat (ACY-1215) is a selective HDAC6 inhibitor with IC50 of 5 nM; >10-fold more selective for HDAC6 than HDAC1/2/3 (class I HDACs) with slight activity against HDAC8, minimal activity against HDAC4/5/7/9/11, Sirtuin1, and Sirtuin2.

  • ACY-738

    ACY-738 demonstrates inhibitory activity against recombinant HDAC6 with IC50 values of 1.7 nM, with respective average selectivity over class I HDACs being 100-fold.

  • Belinostat

    Belinostat (PXD101) is a novel pan-HDAC inhibitor with IC50 of 27 nM, with activity demonstrated in cisplatin-resistant tumors.

  • BG45

    BG45 is an HDAC class I inhibitor with selectivity for HDAC3 (IC50 = 289 nM). It inhibits HDAC1, HDAC2, and HDAC6 with greatly reduced potency (IC50s = 2, 2.2, and >20 (mu)M, respectively).

  • BML-210

    BML-210 is the novel HDAC inhibitor, and its mechanism of action has not been characterized.

  • BRD73954

    BRD73954 ia a potent and selective HDAC inhibitor with IC50 of 36 nM and 120 nM for HDAC6 and HDAC8, respectively.

  • CAY10603

    CAY10603 is a potent and selective inhibitor of HDAC6 with IC50 of 2 pM, as compared with 271, 252, 0.42, 6851, and 90.7 nM for HDAC1, 2, 3, 8, and 10, respectively.

  • Chidamide

    Chidamide(CS055; HBI-8000) is a class I HDAC inhibitor with IC50s of 95/160/67/733 nM for HDAC1/2/3/8; also inhibits HDAC10/11(IC50=78/432 nM); no inhibition on HDAC4/5/7/9/6(IC50>30 uM).

  • CI-994

    CI-994 (Tacedinaline) is an anti-cancer drug which inhibits HDAC1 with IC50 of 0.57 (mu)M and causes G1 cell cycle arrest.

  • CUDC-101

    CUDC-101 is a potent multitargeted HDAC, EGFR and HER2 inhibitor with IC50 of 4.4, 2.4, and 15.7 nM, respectively.

MORE